Therefore, one could hypothesize that first-line adjuvant treatment preference is rather based on specific patient preferences and less on tumor characteristics, without a difference in the outcome of patients treated with adjuvant BRAF/MEK-inhibition versus anti-PD-1 treatment. Here, BRAF is linked to neoplasm.